cabotegravir | Cabotegravir

Keyword	CPC	PCC	Volume	Score	Length of keyword
cabotegravir	1.92	1	7245	6	12

Keyword	CPC	PCC	Volume	Score
cabotegravir	0.08	1	4951	42
cabotegravir prep	0.93	0.1	818	55
cabotegravir injection	0.53	0.4	4245	18
cabotegravir and rilpivirine	0.52	0.3	5399	67
cabotegravir package insert	0.81	0.6	7580	81
cabotegravir la	1.89	1	2361	35
cabotegravir gsk	0.55	0.3	5207	76
cabotegravir side effects	1.25	0.9	6534	36
cabotegravir mechanism of action	1.1	0.2	8582	31
cabotegravir sodium	0.84	0.6	3844	3
cabotegravir spc	0.39	0.7	9638	39
cabotegravir cost	1.57	0.5	2658	31
cabotegravir brand name	1	0.5	9848	13
cabotegravir rilpivirine injection	1.06	0.4	3582	7
cabotegravir and rilpivirine side effects	0.34	0.7	544	53

Search Results related to cabotegravir on Search Engine

Cabotegravir - Wikipedia
wikipedia.org

https://en.wikipedia.org/wiki/Cabotegravir

WEBCabotegravir, sold under the brand name Vocabria among others, is a antiretroviral medication used for the treatment of HIV/AIDS. It is available in the form of tablets and as an intramuscular injection , as well as in an injectable combination with rilpivirine under the brand name Cabenuva.

DA: 100 PA: 24 MOZ Rank: 35

Cabotegravir - Patient | NIH - Clinicalinfo
hiv.gov

https://clinicalinfo.hiv.gov/en/drugs/cabotegravir-1/patient

WEBFeb 7, 2024 · When used for HIV treatment, cabotegravir is always used with the HIV medicine rilpivirine (brand name: Edurant). For short-term PrEP to reduce the risk of HIV infection in adults and adolescents who weigh at least 77 lb (35 kg), are HIV negative, and are at risk of getting HIV.

DA: 56 PA: 30 MOZ Rank: 38

Cabotegravir Uses, Side Effects & Warnings - Drugs.com
drugs.com

https://www.drugs.com/mtm/cabotegravir.html

WEBMay 23, 2022 · Drug class: Integrase strand transfer inhibitor. Medically reviewed by Drugs.com on May 23, 2022. Written by Cerner Multum. Uses. Side effects. Warnings. Before taking. Dosage. Interactions. What is cabotegravir? Cabotegravir is an antiviral medicine that prevents human immunodeficiency virus (HIV) from multiplying in your body.

DA: 35 PA: 14 MOZ Rank: 94

WHO recommends long-acting cabotegravir for HIV prevention
who.int

https://www.who.int/news/item/28-07-2022-who-recommends-long-acting-cabotegravir-for-hiv-prevention

WEBJul 28, 2022 · WHO today released new guidelines for the use of long-acting injectable cabotegravir (CAB-LA) as pre-exposure prophylaxis (PrEP) for HIV and called for countries to consider this safe and highly effective prevention option for …

DA: 47 PA: 41 MOZ Rank: 34

FDA Approves First Injectable Treatment for HIV Pre-Exposure …
fda.gov

https://www.fda.gov/news-events/press-announcements/fda-approves-first-injectable-treatment-hiv-pre-exposure-prevention

WEBDecember 20, 2021. Today, the U.S. Food and Drug Administration approved Apretude (cabotegravir extended-release injectable suspension) for use in at-risk adults and adolescents weighing at least...

DA: 38 PA: 85 MOZ Rank: 60

Cabotegravir: MedlinePlus Drug Information
medlineplus.gov

https://medlineplus.gov/druginfo/meds/a621010.html

WEBCabotegravir is used as a short-term prevention of human immunodeficiency virus type 1 (HIV-1) infection in certain adults and adolescents 12 years of age or older wighing at least 77 pounds (35 kg). It is used to see if the body can tolerate cabotegravir before receiving the cabotegravir injection and in certain cases of missed doses of ...

DA: 13 PA: 67 MOZ Rank: 21

APRETUDE (cabotegravir) Label - Food and Drug …
fda.gov

https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/215499s000lbl.pdf

WEBAPRETUDE (cabotegravir extended-release injectable suspension), for intramuscular use Initial U.S. Approval: 2021. WARNING: RISK OF DRUG RESISTANCE WITH USE OF APRETUDE FOR HIV-1 PRE-EXPOSURE...

DA: 38 PA: 35 MOZ Rank: 61

Cabotegravir (Oral Route) Proper Use - Mayo Clinic
mayoclinic.org

https://www.mayoclinic.org/drugs-supplements/cabotegravir-oral-route/proper-use/drg-20509570

WEBMar 1, 2024 · For oral dosage form (tablets): For short-term treatment of HIV infection: To assess the tolerability of cabotegravir before receiving Cabenuva: Adults and children 12 years of age and older weighing 35 kilograms (kg) or more—30 milligrams (mg) in combination with 25 mg of rilpivirine once a day for at least 28 days.

DA: 66 PA: 56 MOZ Rank: 28

Cabotegravir (Oral Route) Description and Brand Names - Mayo Clinic
mayoclinic.org

https://www.mayoclinic.org/drugs-supplements/cabotegravir-oral-route/description/drg-20509570

WEBIt is used to assess how well you tolerate cabotegravir before receiving cabotegravir/rilpivirine combination injection (Cabenuva) or in patients who will miss a planned injection of Cabenuva. Cabotegravir is also used for pre-exposure prophylaxis (PrEP) to reduce the risk of HIV-1 infection.

DA: 8 PA: 97 MOZ Rank: 74

Cabotegravir for HIV Prevention in Cisgender Men and …
nejm.org

https://www.nejm.org/doi/full/10.1056/NEJMoa2101016

WEBAug 11, 2021 · Long-acting injectable cabotegravir (CAB-LA) is an integrase strand-transfer inhibitor (INSTI) that is administered as an intramuscular injection into the gluteus muscle.

DA: 63 PA: 43 MOZ Rank: 17